

The following information is prepared for the convenience of Canadian Derivatives Clearing Corporation (CDCC) members and Bourse de Montréal Inc. (the Bourse) approved participants. This document is an unofficial summary of certain terms of the aforementioned adjustment. CDCC and the Bourse accept no responsibility for the accuracy or completeness of the summary. CDCC members and Bourse approved participants must ensure they have reviewed the documentation published by the Issuers involved in this corporate action.



CIRCULAR 151-21

August 25, 2021

**ANTICIPATED CONTRACT ADJUSTMENT
Trillium Therapeutics Inc. (TRIL)
Plan of Arrangement**

The Bourse and CDCC wish to inform you that Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced today that they have entered into a definitive agreement whereby Pfizer Inc. will acquire the outstanding shares of Trillium not already owned by Pfizer, for US\$ 18.50 per share.

The proposed acquisition of Trillium is to be completed by way of a statutory plan of arrangement under the *Business Corporations Act* (British Columbia) and subject to customary closing conditions. Completion of the acquisition is also subject to court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature

In connection with the proposed transaction, Trillium will file with the SEC and the Canadian Securities Administrators (the "CSA") and mail or otherwise make available to its shareholders a proxy statement and management information circular (the "Proxy Statement") regarding the proposed transaction.

PLEASE ENSURE THAT ALL CLIENTS WHO HAVE EITHER LONG OR SHORT POSITIONS IN THIS OPTION CLASS ARE ADVISED OF THIS NOTICE.

For further information, please contact the Market Operations Department at (514) 871-7877. Clearing members may contact the CDCC Corporate Operations Department.

Antonio Discenza
Director Derivatives Trading Operations